Tearsheet

iRadimed (IRMD)

Market Price (4/11/2026): $93.23 | Market Cap: $1.2 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

iRadimed (IRMD)

Market Price (4/11/2026): $93.23
Market Cap: $1.2 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 31%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20%

Low stock price volatility
Vol 12M is 36%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Medical Technology & Healthcare Infrastructure. Themes include MRI-Compatible Patient Monitoring, and MRI-Compatible Medical Devices.

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 45x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 48x, P/EPrice/Earnings or Price/(Net Income) is 53x

Key risks
IRMD key risks include [1] a significant reliance on a limited product portfolio and [2] the vulnerability of its near-monopoly market position to new competition.

0	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 31%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20%
2	Low stock price volatility Vol 12M is 36%
3	Megatrend and thematic drivers Megatrends include Digital Health & Telemedicine, and Medical Technology & Healthcare Infrastructure. Themes include MRI-Compatible Patient Monitoring, and MRI-Compatible Medical Devices.
4	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 45x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 48x, P/EPrice/Earnings or Price/(Net Income) is 53x
5	Key risks IRMD key risks include [1] a significant reliance on a limited product portfolio and [2] the vulnerability of its near-monopoly market position to new competition.

Valuation, Metrics & Events

	4/11/26	2025	2024	2023	2022
Share Price CYE	$93.23	$52.48	$43.99	$39.35	$44.84
Market Cap CYE ($ Bil)	1.2	0.7	0.6	0.5	0.6
Total Debt ($ Bil)	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.1	0.1	0.0	0.0	0.1
Enterprise Value ($ Bil)	1.1	0.7	0.6	0.5	0.6
Valuation Ratios
P/S TTM	14.2	8.9	8.2	8.8	12.5
P/EBIT TTM	45.4	29.5	26.8	29.9	50.6
P/E TTM	52.8	33.7	31.1	36.0	54.0
P/FCF TTM	71.9	48.4	51.7	94.3	52.4
Sector Ratios
P/S TTM (Sector)	3.8	3.3	4.1	4.3	6.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7	-1.3	-2.2
P/E TTM (Sector)	-1.8	-1.3	-2.0	-1.5	-2.2
P/FCF TTM (Sector)	-1.7	-1.2	-2.0	-1.5	-2.5

	4/11/26	2025	2024
Share Price CYE	$93.23	$52.48	$43.99
Market Cap CYE ($ Bil)	1.2	0.7	0.6
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.1	0.1	0.0
Enterprise Value ($ Bil)	1.1	0.7	0.6
Valuation Ratios
P/S TTM	14.2	8.9	8.2
P/EBIT TTM	45.4	29.5	26.8
P/E TTM	52.8	33.7	31.1
P/FCF TTM	71.9	48.4	51.7
Sector Ratios
P/S TTM (Sector)	3.8	3.3	4.1
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7
P/E TTM (Sector)	-1.8	-1.3	-2.0
P/FCF TTM (Sector)	-1.7	-1.2	-2.0

	IRMD	S&P 500
REVENUE GROWTH	GOOD
Rev LTM ($ Bil)	0.1
Rev Chg Q	17.0%	7.5%
Rev Chg LTM	14.4%	6.8%
Rev Chg 3Y Avg	16.4%	5.7%
PROFITABILITY	VERY GOOD
Op Inc LTM ($ Bil)	0.0
CFO LTM ($ Bil)	0.0
Net Inc LTM ($ Bil)	0.0
Op Mgn LTM	31.2%	18.6%
CFO/Rev LTM	29.8%	20.6%
Net Inc Mgn	26.8%	12.8%
VALUATION	VERY HIGH
P/S	14.2	3.2
P/CFO	47.6	15.4
P/FCF	71.9	19.8
P/E	52.8	24.1
STABILITY	VERY GOOD
Debt/Equity	0.00	0.21
Cash/Assets	0.47	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
MRI Compatible IV Infusion Pump Systems Installed Globally	approximately 7,832	12312024	Link
MRI Compatible Patient Vital Signs Monitoring Systems Installed Globally	approximately 2,679	12312024	Link
Total Patents Globally	27	11072025	Link
Active Patents	21	11072025	Link
Backlog for Pump and Monitor Products	Record high, but specific value not disclosed	11032025	Link
Number of Employees	160	6302025	Link

Upcoming
5/04/2026	Earnings Release	Rev: $21 Mil (E) EPS: $0.45 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

iRadimed (IRMD) stock has lost about 5% since 12/31/2025 because of the following key factors:

1. Robust Fourth Quarter 2025 Financial Performance and Increased Dividend Payouts.

iRadimed reported record revenue of $22.7 million for the fourth quarter of 2025, marking a 17% increase year-over-year and exceeding analyst expectations. The company also achieved a non-GAAP diluted earnings per share (EPS) of $0.54, surpassing analyst estimates by 17.39% compared to the anticipated $0.46. Additionally, iRadimed demonstrated confidence in its financial health by increasing its regular quarterly cash dividend to $0.20 per share from $0.17 per share, payable on March 6, 2026. These strong financial results and improved shareholder returns contributed to the stock's stability.

2. Anticipation and Initial Rollout of the Next-Generation MRidium® 3870 IV Infusion Pump System.

The company received FDA 510(k) clearance for its new MRidium® 3870 IV Infusion Pump System in July 2025, with initial units delivered in the fourth quarter of 2025. A general sales release is scheduled to begin in April 2026, and management projects this new product to significantly contribute to revenue growth, targeting a $50 million annual revenue run rate for pumps and an overall $100 million-plus revenue run rate during 2026. Positive market feedback and additional orders for the 3870 system indicate future growth potential, helping to maintain investor confidence and the stock's valuation.

Show more

Stock Movement Drivers

Fundamental Drivers

The -3.8% change in IRMD stock from 12/31/2025 to 4/10/2026 was primarily driven by a -9.2% change in the company's P/E Multiple.

(LTM values as of)	12312025	4102026	Change
Stock Price ($)	97.09	93.40	-3.8%
Change Contribution By:
Total Revenues ($ Mil)	81	84	4.1%
Net Income Margin (%)	26.3%	26.8%	1.9%
P/E Multiple	58.3	52.9	-9.2%
Shares Outstanding (Mil)	13	13	-0.1%
Cumulative Contribution			-3.8%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/10/2026

	Return	Correlation
IRMD	-3.8%
Market (SPY)	-5.4%	29.0%
Sector (XLV)	-4.8%	21.8%

Fundamental Drivers

The 32.5% change in IRMD stock from 9/30/2025 to 4/10/2026 was primarily driven by a 21.9% change in the company's P/E Multiple.

(LTM values as of)	9302025	4102026	Change
Stock Price ($)	70.51	93.40	32.5%
Change Contribution By:
Total Revenues ($ Mil)	78	84	8.0%
Net Income Margin (%)	26.6%	26.8%	0.8%
P/E Multiple	43.4	52.9	21.9%
Shares Outstanding (Mil)	13	13	-0.2%
Cumulative Contribution			32.5%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/10/2026

	Return	Correlation
IRMD	32.5%
Market (SPY)	-2.9%	29.2%
Sector (XLV)	6.3%	19.0%

Fundamental Drivers

The 80.6% change in IRMD stock from 3/31/2025 to 4/10/2026 was primarily driven by a 55.2% change in the company's P/E Multiple.

(LTM values as of)	3312025	4102026	Change
Stock Price ($)	51.72	93.40	80.6%
Change Contribution By:
Total Revenues ($ Mil)	73	84	14.4%
Net Income Margin (%)	26.3%	26.8%	2.1%
P/E Multiple	34.1	52.9	55.2%
Shares Outstanding (Mil)	13	13	-0.4%
Cumulative Contribution			80.6%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/10/2026

	Return	Correlation
IRMD	80.6%
Market (SPY)	16.3%	37.4%
Sector (XLV)	2.3%	32.5%

Fundamental Drivers

The 147.4% change in IRMD stock from 3/31/2023 to 4/10/2026 was primarily driven by a 57.2% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312023	4102026	Change
Stock Price ($)	37.76	93.40	147.4%
Change Contribution By:
Total Revenues ($ Mil)	53	84	57.2%
Net Income Margin (%)	24.1%	26.8%	11.4%
P/E Multiple	37.0	52.9	43.0%
Shares Outstanding (Mil)	13	13	-1.3%
Cumulative Contribution			147.4%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/10/2026

	Return	Correlation
IRMD	147.4%
Market (SPY)	63.3%	32.7%
Sector (XLV)	19.1%	25.7%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
IRMD Return	103%	-38%	75%	17%	80%	-2%	359%
Peers Return	0%	-20%	15%	13%	10%	7%	23%
S&P 500 Return	27%	-19%	24%	23%	16%	-0%	82%
Monthly Win Rates [3]
IRMD Win Rate	83%	33%	75%	75%	58%	50%
Peers Win Rate	44%	48%	52%	50%	58%	60%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
IRMD Max Drawdown	-2%	-41%	0%	-15%	-11%	-4%
Peers Max Drawdown	-11%	-30%	-14%	-7%	-16%	-6%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: GEHC, MASI, OSIS, MDT, BDX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)

How Low Can It Go

Unique Key	Event	IRMD	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-49.4%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	97.5%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	755 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-41.9%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	72.1%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	406 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-51.4%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	105.7%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	732 days	120 days

Compare to GEHC, MASI, OSIS, MDT, BDX

In The Past

iRadimed's stock fell -49.4% during the 2022 Inflation Shock from a high on 3/28/2022. A -49.4% loss requires a 97.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About iRadimed (IRMD)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

AI Analysis | Feedback

They're like Medtronic or Baxter, but exclusively for MRI-compatible medical devices.
Think of them as the Philips Healthcare of MRI-safe patient monitoring and IV infusion systems.

AI Analysis | Feedback

MRidium MRI Compatible IV Infusion Pump System: An intravenous infusion pump system designed to function safely and accurately within the magnetic environment of an MRI scanner.
MRI Compatible Patient Vital Signs Monitoring System: A system used to monitor critical patient vital signs safely and effectively during MRI procedures.
Non-Magnetic IV Poles: Intravenous poles constructed from non-magnetic materials to ensure safety and compatibility within MRI environments.
Wireless Remote Displays/Controls: Components that allow for remote operation and monitoring of medical devices used in MRI settings.
Side Car Pump Modules: Additional pump modules that can be integrated with existing infusion systems to expand functionality.
Dose Error Reduction Systems: Technologies implemented to minimize medication errors during intravenous drug administration in medical settings.
SpO2 Monitoring with Sensors and Accessories: Devices and components for monitoring blood oxygen saturation levels, compatible for use in MRI environments.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Roger Susi
FOUNDER, PRESIDENT, AND CEO

Mr. Susi is the founder of iRadimed and has served as a member of the Board since the company's inception. He also founded, served as Chairman, and Chief Executive Officer of Invivo Research Inc., a medical device company and the predecessor to Invivo Corporation, which pioneered MRI-safe patient monitoring. Mr. Susi has over 40 years of management experience in the medical device industry. He resumed his duties as Chief Executive Officer and President of iRadimed in May 2020, having previously held these roles from the company's incorporation until August 2019.

John "Jack" Glenn
CHIEF FINANCIAL OFFICER

Mr. Glenn has served as Chief Financial Officer of iRadimed since 2022. He is a financial executive with over 30 years of experience directing corporate finance activities for both public and private companies. Prior to joining iRadimed, Mr. Glenn served as Chief Financial Officer at Esko Bionics. His extensive experience also includes CFO roles at Sonendo, Armetheon, Solta Medical, Cholestech, and Invivo Corporation. Notably, he assisted Solta Medical in its strategic acquisition by Valeant Pharmaceutical, and was involved when Cholestech was acquired by Alere Medical, and Invivo Corporation was sold to Intermagnetics General Corporation.

Jeffery Chiprin
CHIEF COMMERCIAL OFFICER

Mr. Chiprin has served as iRadimed's Chief Commercial Officer since November 2024, bringing over 30 years of senior leadership experience in medical technology from both private and public sectors. He was previously with Invivo Corporation, joining in 1996 and serving as Vice President of North American Sales for six years. He was part of the leadership team that facilitated the sale of Invivo Corporation to Philips Corporation. Following this, he spent 14 years as Vice President of Sales at Philips Corporation, and later served as Sr. Vice President of Worldwide Sales in private companies specializing in innovative MRI solutions.

Chris Williamson
EXECUTIVE VICE PRESIDENT OF CONTINUOUS IMPROVEMENT AND INFORMATION TECHNOLOGY

Mr. Williamson serves as the Executive Vice President of Continuous Improvement and Information Technology, where he is responsible for leading transformation initiatives aimed at supporting growth, maximizing operational efficiency, and enhancing profitability. He possesses over 20 years of experience in technology, business transformation, and operations within highly regulated industries.

AI Analysis | Feedback

iRadimed Corporation (IRMD) faces several key risks inherent to its specialized niche in MRI-compatible medical devices. These risks primarily stem from its concentrated product portfolio, the demanding regulatory environment, and vulnerabilities within its supply chain.

Key Risks to the Business:

Dependence on a Limited Product Range: iRadimed's financial performance is significantly reliant on a few core products, mainly its MRidium MRI compatible IV infusion pump systems and the 3880 MRI compatible patient vital signs monitoring system. This product concentration makes the company susceptible to market shifts, technological advancements, or any disruptions affecting these specific offerings, which could render them less competitive.
Regulatory Challenges and FDA Scrutiny: As a manufacturer of medical devices, iRadimed operates within a stringent regulatory landscape governed by the FDA and other international bodies. Increased scrutiny on 510(k) clearances, slower approval times for new devices, changes in regulations, or issues of non-compliance could lead to costly penalties, product recalls, operational restrictions, or delays in launching new products. The company has previously received an FDA warning letter related to software updates requiring new 510(k) submissions.
Supply Chain Vulnerabilities: iRadimed's reliance on third-party and, in some cases, single-source suppliers for critical components exposes it to potential supply chain disruptions. Such disruptions could result in manufacturing delays or interruptions, impacting the company's ability to meet customer demand and fulfill sales agreements. Global trade tensions also present a risk to the stability of its supply chain and overall input costs.

AI Analysis | Feedback

null

AI Analysis | Feedback

iRadimed (IRMD) operates in two primary addressable markets: MRI-compatible intravenous (IV) infusion pump systems and MRI-compatible patient vital signs monitoring systems.

MRI Compatible IV Infusion Pump Systems

The global market for MRI-compatible IV infusion pump systems was valued at approximately USD 381.16 million in 2025. This market is projected to grow to approximately USD 614.98 million by 2031, exhibiting a compound annual growth rate (CAGR) of 8.30% during this period. North America is a leading region in this market, holding a 44.10% share in 2025.

MRI Compatible Patient Vital Signs Monitoring Systems

The global MRI-compatible patient monitoring systems market is projected to be valued at approximately USD 4.3 billion in 2025. This market is expected to reach approximately USD 6.4 billion by 2035, growing at a CAGR of 4.0%. Another estimate places the global MRI monitoring devices market size at US$4.2 billion in 2025, anticipated to reach US$5.6 billion by 2032 with a CAGR of 4.2%. North America is identified as the largest market for MRI-compatible patient monitoring systems.

AI Analysis | Feedback

iRadimed (IRMD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:

Launch and Replacement Cycle of the New 3870 MRI-Compatible IV Infusion Pump System: The company anticipates a significant increase in revenue from the introduction and widespread adoption of its next-generation 3870 MRI-compatible IV infusion pump. This new pump, with enhanced usability and technology, is expected to catalyze a major replacement cycle for existing legacy pump systems among hospitals and imaging centers, as well as attract new customers. Management is targeting a $100 million-plus annual revenue run rate in 2026, with initial shipments commencing in late 2025 and a full general sales release in April 2026, leading to significant revenue contributions in the second half of 2026.
Growth in Patient Vital Signs Monitoring Systems and Disposables: The existing patient vital signs monitoring systems and associated disposable products are expected to continue contributing to revenue growth. The company has observed consistent gains in these product lines, with disposable revenue increasing due to higher utilization of its devices.
International Market Expansion: iRadimed plans to expand its market presence geographically, specifically targeting Europe by the end of 2026 and Japan by the summer of 2027. This expansion into new international markets is anticipated to broaden the company's reach for its MRI-compatible infusion systems and monitoring products.
Sustained Demand and Backlog for Legacy 3860 Pumps: Even with the introduction of the new 3870 pump, the legacy 3860 MRI-compatible infusion pump systems continue to experience strong demand. The company expects to maintain quarterly revenue in the first half of 2026, partly driven by the existing backlog of 3860 pumps.
Higher Average Selling Price (ASP) of the 3870 Pump: The new 3870 pump is expected to command a higher average selling price compared to its predecessor. This increased pricing power for the advanced product is anticipated to directly contribute to augmented revenue.

AI Analysis | Feedback

Share Repurchases

iRadimed reported net share repurchases of $2.6 million in 2025.

Share Issuance

No significant share issuances were reported in the last 3-5 years; the net figure for common shares in 2025 reflected a repurchase.

Outbound Investments

iRadimed has not completed any acquisitions in the last few years, though it evaluates such opportunities.

Capital Expenditures

Capital expenditures for the fiscal year 2025 were approximately $7.0 million and $8.2 million in 2024, primarily related to the construction of a new corporate office building which was completed in 2025.
In November 2022, the company acquired approximately 27 acres of land in Orlando, Florida, for $7.3 million, related to its new facility.

Interactive Breakdown

null

null

Better Bets vs. iRadimed (IRMD)

INDUSTRY: Life Sciences Tools & Services

Higher Rev Chg 3Y Avg | Lower P/S (Values for IRMD: 16.4% | 14.2x)

NTRA (41.5% | 11.6x)

Natera

MEDP (20.3% | 5.5x)

Medpace

GH (29.8% | 10.3x)

Guardant Health

IRTC (22.1% | 5.0x)

iRhythm

TWST (22.0% | 7.5x)

Twist Bioscience

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for IRMD: 16.4% | 45.5x)

MEDP (20.3% | 26.1x)

Medpace

VMD (25.0% | 17.5x)

Viemed Healthcare

SNWV (38.9% | 29.2x)

SANUWAVE Health

XTNT (33.4% | 9.2x)

Xtant Medical

Higher Rev Chg LTM (Value for IRMD: 14.4%)

NTRA (35.9%)

Natera

GH (32.9%)

Guardant Health

IRTC (26.2%)

iRhythm

MEDP (20.0%)

Medpace

TWST (18.6%)

Twist Bioscience

Higher Rev Chg 3Y Avg (Value for IRMD: 16.4%)

NTRA (41.5%)

Natera

GH (29.8%)

Guardant Health

IRTC (22.1%)

iRhythm

TWST (22.0%)

Twist Bioscience

MEDP (20.3%)

Medpace

Higher CFO/Rev LTM (Value for IRMD: 29.8%)

QGEN (31.3%)

Qiagen

Higher FCF/Rev LTM (Value for IRMD: 19.7%)

MEDP (26.9%)

Medpace

ILMN (21.4%)

Illumina

DHR (21.4%)

Danaher

QGEN (21.4%)

Qiagen

MTD (21.1%)

Mettler-Toledo International

Higher Total Yield (Value for IRMD: 2.3%)

A (4.8%)

Agilent Technologies

IQV (4.8%)

IQVIA

TMO (3.6%)

Thermo Fisher Scientific

MTD (3.2%)

Mettler-Toledo International

DHR (2.7%)

Danaher

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for IRMD: 16.4% | 14.2x)

LLY (32.1% | 12.9x)

Eli Lilly

BSX (16.6% | 4.6x)

Boston Scientific

ALNY (54.8% | 11.5x)

Alnylam Pharmaceuticals

NTRA (41.5% | 11.6x)

Natera

UTHR (18.1% | 7.8x)

United Therapeutics

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for IRMD: 16.4% | 45.5x)

LLY (32.1% | 28.3x)

Eli Lilly

BSX (16.6% | 23.1x)

Boston Scientific

UTHR (18.1% | 16.4x)

United Therapeutics

DXCM (17.1% | 27.1x)

DexCom

MEDP (20.3% | 26.1x)

Medpace

Higher Rev Chg LTM (Value for IRMD: 14.4%)

ALNY (65.2%)

Alnylam Pharmaceuticals

LLY (44.7%)

Eli Lilly

ISRG (20.5%)

Intuitive Surgical

BSX (19.9%)

Boston Scientific

MCK (15.5%)

McKesson

Higher Rev Chg 3Y Avg (Value for IRMD: 16.4%)

ALNY (54.8%)

Alnylam Pharmaceuticals

INSM (36.8%)

Insmed

LLY (32.1%)

Eli Lilly

ISRG (17.4%)

Intuitive Surgical

BSX (16.6%)

Boston Scientific

Higher Op Mgn LTM (Value for IRMD: 31.2%)

LLY (45.6%)

Eli Lilly

GILD (39.7%)

Gilead Sciences

VRTX (37.9%)

Vertex Pharmaceuticals

MRK (34.0%)

Merck

ABBV (32.8%)

AbbVie

Higher CFO/Rev LTM (Value for IRMD: 29.8%)

REGN (34.7%)

Regeneron Pharmaceuticals

GILD (34.0%)

Gilead Sciences

ABBV (31.1%)

AbbVie

VRTX (30.3%)

Vertex Pharmaceuticals

ISRG (30.1%)

Intuitive Surgical

Higher FCF/Rev LTM (Value for IRMD: 19.7%)

GILD (32.1%)

Gilead Sciences

ABBV (29.1%)

AbbVie

ISRG (24.7%)

Intuitive Surgical

AMGN (22.0%)

Amgen

JNJ (20.5%)

Johnson & Johnson

Higher Total Yield (Value for IRMD: 2.3%)

MRK (8.8%)

Merck

UNH (7.2%)

UnitedHealth

JNJ (6.8%)

Johnson & Johnson

ABBV (4.3%)

AbbVie

LLY (3.1%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for IRMD: 16.4% | 14.2x)

META (19.9% | 7.9x)

Meta Platforms

BRK-B (27.0% | 2.5x)

Berkshire Hathaway

MU (45.3% | 8.1x)

Micron Technology

GE (18.3% | 7.1x)

GE Aerospace

APH (24.1% | 7.5x)

Amphenol

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for IRMD: 16.4% | 45.5x)

NVDA (101.8% | 35.2x)

NVIDIA

META (19.9% | 19.1x)

Meta Platforms

MU (45.3% | 16.8x)

Micron Technology

GE (18.3% | 37.4x)

GE Aerospace

APH (24.1% | 28.9x)

Amphenol

Higher Rev Chg LTM (Value for IRMD: 14.4%)

NVDA (65.5%)

NVIDIA

AVGO (25.2%)

Broadcom

META (22.2%)

Meta Platforms

MSFT (16.7%)

Microsoft

GOOGL (15.1%)

Alphabet

Higher Rev Chg 3Y Avg (Value for IRMD: 16.4%)

NVDA (101.8%)

NVIDIA

MU (45.3%)

Micron Technology

BRK-B (27.0%)

Berkshire Hathaway

AVGO (26.2%)

Broadcom

META (19.9%)

Meta Platforms

Higher Op Mgn LTM (Value for IRMD: 31.2%)

NVDA (60.4%)

NVIDIA

MSFT (46.7%)

Microsoft

AVGO (41.5%)

Broadcom

AAPL (32.4%)

Apple

GOOGL (32.0%)

Alphabet

Higher CFO/Rev LTM (Value for IRMD: 29.8%)

MSFT (52.5%)

Microsoft

NVDA (47.6%)

NVIDIA

AVGO (43.5%)

Broadcom

GOOGL (40.9%)

Alphabet

AAPL (31.1%)

Apple

Higher FCF/Rev LTM (Value for IRMD: 19.7%)

NVDA (44.8%)

NVIDIA

AVGO (42.3%)

Broadcom

AAPL (28.3%)

Apple

MSFT (25.3%)

Microsoft

META (22.9%)

Meta Platforms

Higher Total Yield (Value for IRMD: 2.3%)

MSFT (5.2%)

Microsoft

GOOGL (3.7%)

Alphabet

AAPL (3.5%)

Apple

AMZN (3.0%)

Amazon.com

NVDA (2.6%)

NVIDIA

Best Bets in Health Care

What You Pay

P/EBIT (Value for IRMD: 45.5x)

RPRX (12.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.0x)

Veeva Systems

HALO (16.5x)

Halozyme Therapeutics

UTHR (14.3x)

United Therapeutics

CPRX (11.9x)

Catalyst Pharmaceuticals

BMY (10.6x)

Bristol-Myers Squibb

RMD (18.1x)

ResMed

AMGN (16.1x)

Amgen

PBH (8.8x)

Prestige Consumer Healthcare

P/E (Value for IRMD: 52.9x)

RPRX (26.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.3x)

Veeva Systems

HALO (25.2x)

Halozyme Therapeutics

UTHR (18.6x)

United Therapeutics

CPRX (14.3x)

Catalyst Pharmaceuticals

BMY (16.9x)

Bristol-Myers Squibb

RMD (22.5x)

ResMed

AMGN (24.5x)

Amgen

PBH (14.5x)

Prestige Consumer Healthcare

What You Get

Rev Chg 3Y Avg (Value for IRMD: 16.4%)

RPRX (2.1%)

Royalty Pharma

DOCS (16.7%)

Doximity

VEEV (14.1%)

Veeva Systems

HALO (28.5%)

Halozyme Therapeutics

UTHR (18.1%)

United Therapeutics

CPRX (43.1%)

Catalyst Pharmaceuticals

BMY (1.5%)

Bristol-Myers Squibb

RMD (12.9%)

ResMed

AMGN (11.9%)

Amgen

PBH (-0.1%)

Prestige Consumer Healthcare

Rev Chg LTM (Value for IRMD: 14.4%)

RPRX (5.1%)

Royalty Pharma

DOCS (15.9%)

Doximity

VEEV (16.3%)

Veeva Systems

HALO (37.6%)

Halozyme Therapeutics

UTHR (10.6%)

United Therapeutics

CPRX (19.8%)

Catalyst Pharmaceuticals

BMY (-0.2%)

Bristol-Myers Squibb

RMD (9.6%)

ResMed

AMGN (10.0%)

Amgen

PBH (-1.3%)

Prestige Consumer Healthcare

Rev Chg Q (Value for IRMD: 17.0%)

RPRX (4.8%)

Royalty Pharma

DOCS (9.8%)

Doximity

VEEV (16.0%)

Veeva Systems

HALO (51.6%)

Halozyme Therapeutics

UTHR (7.4%)

United Therapeutics

CPRX (7.6%)

Catalyst Pharmaceuticals

BMY (1.3%)

Bristol-Myers Squibb

RMD (11.0%)

ResMed

AMGN (8.6%)

Amgen

PBH (-2.4%)

Prestige Consumer Healthcare

FCF/Rev 3Y Avg (Value for IRMD: 17.0%)

RPRX (118.0%)

Royalty Pharma

DOCS (41.6%)

Doximity

VEEV (40.8%)

Veeva Systems

HALO (38.8%)

Halozyme Therapeutics

UTHR (34.1%)

United Therapeutics

CPRX (33.2%)

Catalyst Pharmaceuticals

BMY (27.9%)

Bristol-Myers Squibb

RMD (27.3%)

ResMed

AMGN (26.4%)

Amgen

PBH (22.3%)

Prestige Consumer Healthcare

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	iRadimed Earnings Notes	12/16/2025
2	Can iRadimed Stock Hold Up When Markets Turn?	10/17/2025
3	iRadimed Total Shareholder Return (TSR): 18.2% in 2024 and 10.7% 3-yr compounded annual returns (above peer average)	03/07/2025
4	iRadimed (IRMD) Operating Cash Flow Comparison	02/17/2025
5	iRadimed (IRMD) Net Income Comparison	02/15/2025
6	iRadimed (IRMD) Operating Income Comparison	02/15/2025
7	iRadimed (IRMD) Revenue Comparison	02/13/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to IRMD.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03312026	PGNY	Progyny	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	CNC	Centene	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	OSCR	Oscar Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.0%	3.0%	-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper	03202026	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.4%	-0.4%	-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%	03202026	GILD	Gilead Sciences	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	1.6%	1.6%	-2.2%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
OGN	Organon	2.3	27.8%	23.5%
LWLG	Lightwave Logic	1.4	25.6%	227.2%
POET	POET Technologies	0.6	15.8%	11.2%
ALAB	Astera Labs	25.3	15.1%	-10.4%
MANE	Veradermics	1.4	14.7%	82.3%
TTMI	TTM Technologies	12.6	13.0%	76.1%
AAOI	Applied Optoelectronics	10.6	13.0%	332.0%
FBYD	Falcons Beyond Global	0.5	12.6%	-18.9%
TE	T1 Energy	0.8	12.2%	-29.8%
CRWV	CoreWeave	51.7	10.9%	42.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FSLY	Fastly	3.5	-21.7%	126.6%
REPL	Replimune	0.4	-19.5%	-51.0%
AKAM	Akamai Technologies	13.2	-16.7%	4.7%
FICO	Fair Isaac	21.9	-14.0%	-45.4%
SEZL	Sezzle	2.0	-13.6%	-5.9%
NET	Cloudflare	58.6	-13.5%	-15.3%
DOCN	DigitalOcean	6.9	-13.3%	57.1%
SMPL	Simply Good Foods	1.0	-11.5%	-48.0%
EVMN	Evommune	0.8	-11.0%	49.0%
GH	Guardant Health	10.1	-9.8%	-23.0%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
AEHR	Aehr Test Systems	2.1	58.9%	248.8%
CAR	Avis Budget	10.6	57.5%	133.7%
AAOI	Applied Optoelectronics	10.6	44.9%	332.0%
OGN	Organon	2.3	38.8%	23.5%
LWLG	Lightwave Logic	1.4	38.4%	227.2%
HUT	Hut 8	7.2	37.4%	43.9%
SLNO	Soleno Therapeutics	2.8	33.3%	13.7%
STAA	Staar Surgical	1.3	30.8%	14.5%
RIOT	Riot Platforms	5.8	29.1%	31.0%
CIFR	Cipher Digital	6.6	28.9%	12.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
REPL	Replimune	0.4	-43.4%	-51.0%
FSLY	Fastly	3.5	-31.1%	126.6%
SMPL	Simply Good Foods	1.0	-26.3%	-48.0%
AKAM	Akamai Technologies	13.2	-22.6%	4.7%
GWRE	Guidewire Software	10.0	-21.8%	-41.3%
OKTA	Okta	11.2	-21.5%	-27.2%
HUBS	HubSpot	10.1	-21.4%	-52.1%
NET	Cloudflare	58.6	-21.1%	-15.3%
VRDN	Viridian Therapeutics	1.4	-20.6%	-52.0%
SNOW	Snowflake	41.5	-20.2%	-44.8%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
XLO	Xilio Therapeutics	0.6	1475.9%	-5.1%
CAR	Avis Budget	10.6	196.4%	133.7%
SATL	Satellogic	1.0	135.7%	292.0%
LWLG	Lightwave Logic	1.4	111.2%	227.2%
APLS	Apellis Pharmaceuticals	5.2	110.5%	62.4%
FBYD	Falcons Beyond Global	0.5	92.1%	-18.9%
FLY	Firefly Aerospace	6.0	82.2%	67.8%
KOD	Kodiak Sciences	2.3	75.7%	54.2%
KODK	Eastman Kodak	1.2	74.0%	42.9%
ORKA	Oruka Therapeutics	3.2	73.1%	96.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.3	-49.0%	-57.8%
VRDN	Viridian Therapeutics	1.4	-47.8%	-52.0%
MAZE	Maze Therapeutics	1.2	-47.1%	-35.6%
BUR	Burford Capital	1.0	-47.0%	-51.1%
FRMI	Fermi	2.9	-43.9%	-39.1%
TE	T1 Energy	0.8	-42.4%	-29.8%
REPL	Replimune	0.4	-39.7%	-51.0%
ADMA	ADMA Biologics	2.3	-38.1%	-46.8%
FIG	Figma	9.3	-34.8%	-51.4%
BOBS	Bobs Discount Furniture	1.4	-34.7%	-34.8%

Peer Comparisons

Peers to compare with:

Financials

	IRMD	GEHC	MASI	OSIS	MDT	BDX	Median
Name	iRadimed	GE Healt.	Masimo	OSI Syst.	Medtronic	Becton D.
Mkt Price	93.40	73.18	178.32	293.39	87.21	154.22	123.81
Mkt Cap	1.2	33.2	9.3	4.9	111.9	44.0	21.2
Rev LTM	84	20,625	1,527	1,798	35,483	21,924	11,212
Op Inc LTM	26	2,762	313	231	6,611	3,104	1,537
FCF LTM	17	1,505	193	119	5,410	2,631	849
FCF 3Y Avg	13	1,590	119	18	5,269	2,738	854
CFO LTM	25	1,987	218	162	7,285	3,394	1,102
CFO 3Y Avg	21	2,013	169	59	7,016	3,491	1,091

Growth & Margins

	IRMD	GEHC	MASI	OSIS	MDT	BDX	Median
Name	iRadimed	GE Healt.	Masimo	OSI Syst.	Medtronic	Becton D.
Rev Chg LTM	14.4%	4.8%	9.4%	9.0%	6.9%	6.2%	7.9%
Rev Chg 3Y Avg	16.4%	4.0%	-6.2%	14.8%	4.9%	5.4%	5.1%
Rev Chg Q	17.0%	7.1%	12.0%	10.5%	8.7%	1.6%	9.6%
QoQ Delta Rev Chg LTM	4.1%	1.9%	3.0%	2.5%	2.1%	0.4%	2.3%
Op Mgn LTM	31.2%	13.4%	20.5%	12.8%	18.6%	14.2%	16.4%
Op Mgn 3Y Avg	30.6%	13.1%	13.1%	12.8%	18.5%	13.3%	13.2%
QoQ Delta Op Mgn LTM	0.3%	-0.1%	9.8%	-0.1%	-0.7%	0.5%	0.1%
CFO/Rev LTM	29.8%	9.6%	14.3%	9.0%	20.5%	15.5%	14.9%
CFO/Rev 3Y Avg	28.4%	10.1%	11.9%	3.6%	20.8%	16.9%	14.4%
FCF/Rev LTM	19.7%	7.3%	12.6%	6.6%	15.2%	12.0%	12.3%
FCF/Rev 3Y Avg	17.0%	8.0%	8.2%	1.1%	15.7%	13.3%	10.7%

Valuation

	IRMD	GEHC	MASI	OSIS	MDT	BDX	Median
Name	iRadimed	GE Healt.	Masimo	OSI Syst.	Medtronic	Becton D.
Mkt Cap	1.2	33.2	9.3	4.9	111.9	44.0	21.2
P/S	14.2	1.6	6.1	2.7	3.2	2.0	2.9
P/EBIT	45.5	10.3	30.4	22.2	17.8	17.1	20.0
P/E	52.9	15.9	-61.3	32.1	24.2	25.1	24.7
P/CFO	47.7	16.7	42.7	30.4	15.4	13.0	23.5
Total Yield	2.3%	6.5%	-1.6%	3.1%	7.4%	6.7%	4.8%
Dividend Yield	0.4%	0.2%	0.0%	0.0%	3.2%	2.7%	0.3%
FCF Yield 3Y Avg	1.6%	4.4%	1.6%	0.3%	4.7%	4.3%	2.9%
D/E	0.0	0.3	0.1	0.2	0.3	0.4	0.2
Net D/E	-0.0	0.2	0.0	0.1	0.2	0.4	0.2

Returns

	IRMD	GEHC	MASI	OSIS	MDT	BDX	Median
Name	iRadimed	GE Healt.	Masimo	OSI Syst.	Medtronic	Becton D.
1M Rtn	-7.4%	0.8%	1.6%	5.0%	-1.2%	-5.5%	-0.2%
3M Rtn	-5.4%	-16.1%	28.4%	5.2%	-9.9%	-2.6%	-4.0%
6M Rtn	31.5%	3.2%	23.3%	21.5%	-7.2%	6.4%	13.9%
12M Rtn	89.2%	17.8%	17.7%	59.1%	9.0%	0.8%	17.7%
3Y Rtn	136.8%	-8.7%	-5.7%	186.3%	18.7%	-18.0%	6.5%
1M Excs Rtn	-8.0%	0.2%	1.0%	4.4%	-1.8%	-6.1%	-0.8%
3M Excs Rtn	-4.9%	-15.4%	30.8%	6.4%	-9.4%	-2.3%	-3.6%
6M Excs Rtn	21.7%	-3.4%	15.1%	17.1%	-10.4%	1.4%	8.2%
12M Excs Rtn	57.9%	-12.0%	-13.9%	31.6%	-26.9%	-36.8%	-12.9%
3Y Excs Rtn	84.1%	-76.1%	-68.4%	121.8%	-45.3%	-82.7%	-56.8%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	12/31/2025	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	3/6/2026	3/6/2026	3/6/2025	3/1/2024	3/2/2023	3/4/2022	3/5/2021
Key Financials
Total Revenue	84	84	73	66	53	42	32
EBITDA	27	27	23	21	16	11	1
Operating Income	26	26	22	20	16	10	-1
Net Income	22	22	19	17	13	9	1
EPS	1.77	1.77	1.52	1.36	1.02	0.76	0.11
Growth Rates
Total Revenue Growth	14.4%	14.4%	11.7%	23.0%	27.5%	31.8%	-17.7%
EBITDA Growth	19.9%	19.9%	9.5%	27.6%	45.2%	1826.2%	-94.1%
Operating Income Growth	19.0%	19.0%	9.6%	28.2%	59.2%	1398.5%	-108.7%
Net Income Growth	16.9%	16.9%	11.9%	34.0%	37.6%	581.2%	-85.8%
Margins
EBITDA Margin	32.6%	32.6%	31.1%	31.7%	30.6%	26.8%	1.8%
Operating Income Margin	31.2%	31.2%	30.0%	30.6%	29.3%	23.5%	-2.4%
Net Income Margin	26.8%	26.8%	26.3%	26.2%	24.1%	22.3%	4.3%
Cash & Debt
Total Cash	51	51	52	50	58	63	52
Total Debt	0	0	0	2	2	2	3
Net Debt / (Cash)	-51	-51	-52	-48	-56	-60	-49
Cash Flows
Net Cash from Operations	25	25	26	13	10	11	6
Free Cash from Operations	17	17	17	5	8	11	5
Returns to Shareholders
Dividends	15	15	14	13	13	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	3/6/2026	11/3/2025	8/1/2025	5/5/2025	3/6/2025	10/31/2024	8/1/2024	5/2/2024	3/1/2024	11/3/2023	8/3/2023	5/4/2023
Key Financials Quarterly
Total Revenue	23	21	20	20	19	18	18	18	17	17	16	15
Ebitda	7	7	7	6	6	6	6	5	5	6	5	4
Operating Income	7	7	7	5	6	6	6	5	5	6	5	4
Net Income	6	6	6	5	5	5	5	4	5	5	4	3
EPS	0.51	0.44	0.45	0.37	0.41	0.40	0.39	0.33	0.36	0.40	0.33	0.27
Key Financials TTM
Total Revenue TTM	84	81	78	75	73	71	69	68	66	63	60	56
Ebitda TTM	27	26	25	23	23	22	22	22	21	20	18	18
Operating Income TTM	26	25	24	23	22	21	21	21	20	19	17	17
Net Income TTM	22	21	21	20	19	19	19	18	17	16	15	14
Growth Rates Quarterly
Total Revenue Growth	17.0%	15.7%	13.8%	10.9%	11.1%	11.0%	11.1%	13.7%	17.4%	23.1%	26.8%	25.7%
EBITDA Growth	24.7%	20.6%	20.1%	13.1%	11.8%	-1.8%	13.1%	18.7%	26.1%	33.4%	10.5%	19.4%
Operating Income Growth	22.3%	18.0%	20.6%	14.4%	12.4%	-2.0%	13.4%	18.5%	21.3%	42.9%	19.1%	30.3%
Net Income Growth	25.2%	10.4%	17.8%	13.3%	13.4%	-0.3%	17.3%	21.4%	23.6%	47.9%	29.0%	37.0%
Margins Quarterly
EBITDA Margin	32.9%	34.0%	34.3%	28.8%	30.9%	32.7%	32.5%	28.3%	30.7%	36.9%	31.9%	27.1%
Operating Income Margin	31.3%	32.2%	33.3%	27.8%	29.9%	31.6%	31.4%	27.0%	29.6%	35.8%	30.8%	25.9%
Net Income Margin	28.4%	26.3%	28.3%	24.0%	26.5%	27.6%	27.3%	23.5%	26.0%	30.7%	25.9%	22.0%
Cash & Debt
Total Cash	51	57	53	50	52	52	49	45	50	47	46	43
Total Debt	0	0	0	0	0	0	0	2	2	2	2	2
Net Debt / (Cash)	-51	-57	-53	-50	-52	-51	-48	-43	-48	-45	-44	-40
Cash Flows Quarterly
FCF from Operations	6	7	8	4	6	9	7	4	4	1	4	5
Cash Flows TTM
FCF from Operations TTM	25	25	27	26	26	24	16	13	13	13	15	13
Returns to Shareholders Quarterly
Dividends	9	2	2	2	2	2	2	8	0	0	0	13
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-	-	-	-	-	-	-	-	-	-	-	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-	-	-	-	-	-	-	-	-	-	-	-

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI)	73	66
Amortization of extended warranty agreements			2	2	2
Disposables			15	13	11
Ferro Magnetic Detection Systems			0
Magnetic Resonance Imaging (MRI) Compatible Intravenous (IV) Infusion Pump Systems			15	13	9
Magnetic Resonance Imaging (MRI) Compatible Patient Vital Signs Monitoring Systems			22	14	10
Total	73	66	53	42	32

Price Behavior

Price Behavior

Market Price	$93.40
Market Cap ($ Bil)	1.2
First Trading Date	07/16/2014
Distance from 52W High	-11.1%
	50 Days	200 Days
DMA Price	$99.28	$83.37
DMA Trend	up	indeterminate
Distance from DMA	-5.9%	12.0%
	3M	1YR
Volatility	34.2%	35.8%
Downside Capture	0.38	0.28
Upside Capture	68.55	114.89
Correlation (SPY)	26.4%	30.9%

IRMD Betas & Captures as of 3/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.13	1.06	0.75	0.76	0.72	0.77
Up Beta	0.46	0.60	1.29	0.74	0.74	0.82
Down Beta	1.44	1.76	1.21	1.37	0.62	0.68
Up Capture	135%	120%	56%	103%	116%	77%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	12	22	33	76	139	377
Down Capture	101%	73%	38%	6%	60%	86%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	10	19	29	49	111	369

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with IRMD
IRMD	95.3%	36.3%	1.90	-
Sector ETF (XLV)	12.3%	16.8%	0.52	31.7%
Equity (SPY)	31.2%	17.3%	1.47	34.6%
Gold (GLD)	60.1%	27.8%	1.69	4.3%
Commodities (DBC)	29.8%	16.6%	1.58	-1.9%
Real Estate (VNQ)	21.3%	15.2%	1.07	29.4%
Bitcoin (BTCUSD)	-5.7%	43.7%	-0.01	14.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with IRMD
IRMD	33.4%	43.6%	0.80	-
Sector ETF (XLV)	6.3%	14.6%	0.25	25.5%
Equity (SPY)	11.1%	17.0%	0.50	35.1%
Gold (GLD)	22.1%	17.8%	1.02	3.8%
Commodities (DBC)	11.8%	18.8%	0.52	5.8%
Real Estate (VNQ)	3.7%	18.8%	0.10	29.3%
Bitcoin (BTCUSD)	4.0%	56.5%	0.29	19.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with IRMD
IRMD	18.1%	49.4%	0.53	-
Sector ETF (XLV)	9.8%	16.5%	0.48	24.2%
Equity (SPY)	13.8%	17.9%	0.66	30.6%
Gold (GLD)	14.2%	15.9%	0.74	2.9%
Commodities (DBC)	8.6%	17.6%	0.41	11.8%
Real Estate (VNQ)	5.1%	20.7%	0.22	26.3%
Bitcoin (BTCUSD)	67.4%	66.9%	1.07	9.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3312026
Short Interest: Shares Quantity	0.5 Mil
Short Interest: % Change Since 3152026	1.6%
Average Daily Volume	0.1 Mil
Days-to-Cover Short Interest	5.7 days
Basic Shares Quantity	12.7 Mil
Short % of Basic Shares	3.9%

Returns Analyses

	Title
0	Can iRadimed Stock Hold Up When Markets Turn?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
2/10/2026	9.6%	5.1%	5.2%
11/3/2025	9.5%	9.8%	21.6%
8/1/2025	13.4%	18.2%	24.5%
5/5/2025	-2.2%	-3.0%	12.2%
1/10/2025	-0.1%	4.6%	8.1%
10/31/2024	-6.9%	6.2%	2.2%
8/1/2024	-1.2%	-7.5%	1.0%
5/2/2024	4.4%	3.4%	1.5%
...
SUMMARY STATS
# Positive	16	15	18
# Negative	8	9	6
Median Positive	6.1%	6.2%	6.9%
Median Negative	-3.3%	-4.7%	-7.4%
Max Positive	23.7%	28.2%	24.5%
Max Negative	-20.1%	-20.7%	-19.4%

	Forward Returns
2/10/2026	9.6%	5.1%	5.2%
11/3/2025	9.5%	9.8%	21.6%
8/1/2025	13.4%	18.2%	24.5%
5/5/2025	-2.2%	-3.0%	12.2%
1/10/2025	-0.1%	4.6%	8.1%
10/31/2024	-6.9%	6.2%	2.2%
8/1/2024	-1.2%	-7.5%	1.0%
5/2/2024	4.4%	3.4%	1.5%
2/8/2024	0.0%	-1.7%	-5.2%
11/3/2023	9.9%	-2.3%	3.1%
8/3/2023	10.2%	8.9%	5.7%
5/4/2023	7.1%	9.9%	13.0%
1/19/2023	5.4%	10.1%	16.0%
10/11/2022	0.0%	5.4%	3.5%
7/29/2022	6.9%	-4.7%	-17.8%
4/29/2022	-20.1%	-20.7%	-19.4%
2/4/2022	23.7%	28.2%	20.3%
10/29/2021	3.1%	5.0%	23.0%
7/30/2021	-2.4%	4.6%	-2.2%
4/30/2021	3.5%	11.0%	3.9%
2/4/2021	-4.3%	-5.8%	-7.8%
10/30/2020	3.2%	0.8%	11.7%
7/30/2020	0.1%	-1.5%	-7.0%
4/30/2020	-9.0%	-6.6%	4.5%
SUMMARY STATS
# Positive	16	15	18
# Negative	8	9	6
Median Positive	6.1%	6.2%	6.9%
Median Negative	-3.3%	-4.7%	-7.4%
Max Positive	23.7%	28.2%	24.5%
Max Negative	-20.1%	-20.7%	-19.4%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	03/06/2026	10-K
09/30/2025	11/03/2025	10-Q
06/30/2025	08/01/2025	10-Q
03/31/2025	05/05/2025	10-Q
12/31/2024	03/06/2025	10-K
09/30/2024	10/31/2024	10-Q
06/30/2024	08/01/2024	10-Q
03/31/2024	05/02/2024	10-Q
12/31/2023	03/01/2024	10-K
09/30/2023	11/03/2023	10-Q
06/30/2023	08/03/2023	10-Q
03/31/2023	05/04/2023	10-Q
12/31/2022	03/02/2023	10-K
09/30/2022	11/03/2022	10-Q
06/30/2022	08/05/2022	10-Q
03/31/2022	05/06/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 2/10/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
Q1 2026 Revenue	21.00 Mil	21.50 Mil	22.00 Mil
Q1 2026 GAAP Diluted EPS	0.39	0.41	0.43
Q1 2026 Non-GAAP Diluted EPS	0.44	0.46	0.48
2026 Revenue	91.00 Mil	93.50 Mil	96.00 Mil	12.6%		Higher New	Actual: 83.00 Mil for 2025
2026 GAAP Diluted EPS	1.9	1.98	2.05	16.2%		Higher New	Actual: 1.7 for 2025
2026 Non-GAAP Diluted EPS	2.06	2.13	2.21	14.8%		Higher New	Actual: 1.86 for 2025

Prior: Q3 2025 Earnings Reported 11/3/2025

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
Q4 2025 Revenue	21.40 Mil	21.90 Mil	22.40 Mil			Higher New
Q4 2025 GAAP Diluted EPS	0.43	0.45	0.47			Higher New
Q4 2025 Non-GAAP Diluted EPS	0.47	0.49	0.51			Higher New
2025 Revenue	82.50 Mil	83.00 Mil	83.50 Mil	2.2%		Raised	Guidance: 81.25 Mil for 2025
2025 GAAP Diluted EPS	1.68	1.7	1.72	3.0%		Raised	Guidance: 1.65 for 2025
2025 Non-GAAP Diluted EPS	1.84	1.86	1.88	2.8%		Raised	Guidance: 1.81 for 2025

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	1062026	97.68	5,000	488,417	222,474,062	Form
2	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	12302025	97.66	5,000	488,317	222,916,555	Form
3	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	12222025	96.73	5,000	483,672	221,279,867	Form
4	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	12172025	96.75	5,000	483,729	221,789,724	Form
5	Glenn, John	CHIEF FINANCIAL OFFICER	Direct	Sell	12122025	97.29	15,000	1,459,342	716,245	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	1062026	97.68	5,000	488,417	222,474,062	Form
2	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	12302025	97.66	5,000	488,317	222,916,555	Form
3	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	12222025	96.73	5,000	483,672	221,279,867	Form
4	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	12172025	96.75	5,000	483,729	221,789,724	Form
5	Glenn, John	CHIEF FINANCIAL OFFICER	Direct	Sell	12122025	97.29	15,000	1,459,342	716,245	Form
6	Hawkins, James B		Direct	Sell	12102025	96.61	3,000	289,838	2,776,836	Form
7	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	12092025	95.43	5,000	477,163	219,256,564	Form
8	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	12022025	92.76	5,000	463,794	213,577,192	Form
9	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	11242025	90.36	5,000	451,814	208,512,327	Form
10	Hawkins, James B		Direct	Sell	11212025	88.24	3,000	264,717	2,695,255	Form
11	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	11192025	85.59	5,000	427,957	197,930,242	Form
12	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	11122025	85.24	5,000	426,193	197,540,289	Form
13	Glenn, John	CHIEF FINANCIAL OFFICER	Direct	Sell	11122025	84.51	10,651	900,162	211,286	Form
14	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	11042025	82.64	5,000	413,216	191,938,832	Form
15	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	10272025	77.69	5,000	388,429	180,813,923	Form
16	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	10212025	74.82	5,000	374,081	174,508,828	Form
17	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	10142025	72.59	5,000	362,964	169,685,778	Form
18	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	10072025	71.72	5,000	358,614	168,010,659	Form
19	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	10022025	70.19	5,000	350,957	164,774,382	Form
20	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	9242025	71.26	5,000	356,290	167,634,680	Form
21	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	9182025	71.27	5,000	356,367	168,027,155	Form
22	Allen, Monty K		Direct	Sell	8062025	69.10	1,102	76,148	1,374,952	Form
23	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	1212026	101.84	5,000	509,225	230,933,533	Form
24	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	1132026	97.45	5,000	487,231	221,446,326	Form
25	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	1272026	100.65	5,000	503,255	227,722,996	Form
26	Allen, Monty K		Direct	Sell	2132026	100.26	1,000	100,256	2,105,382	Form
27	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	3092026	98.39	7,500	737,919	221,867,646	Form
28	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	3182026	101.38	5,000	506,895	227,342,632	Form
29	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	3182026	102.43	2,500	256,075	229,443,200	Form
30	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	3252026	100.38	5,000	501,912	224,354,664	Form
31	Susi, Roger E	CEO, PRESIDENT, CHAIRMAN	Phillip Susi 2008 Dynasty Trust	Sell	3252026	100.28	2,500	250,697	223,872,600	Form
32	Susi, Roger E	CEO, President, Chairman	Phillip Susi 2008 Dynasty Trust	Sell	4012026	95.02	7,500	712,614	211,408,835	Form
33	Susi, Roger E	CEO, President, Chairman	Phillip Susi 2008 Dynasty Trust	Sell	4072026	96.02	5,000	480,110	213,168,640	Form
34	Susi, Roger E	CEO, President, Chairman	Phillip Susi 2008 Dynasty Trust	Sell	4072026	94.84	2,500	237,098	210,305,961	Form

IRMD Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing IRMD?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What IRMD Makes & Who Pays

TTM figures based on

IRMD Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

iRadimed (IRMD)

Market Price (4/11/2026): $93.23 | Market Cap: $1.2 BilSector: Health Care | Industry: Life Sciences Tools & Services

iRadimed (IRMD)

Market Price (4/11/2026): $93.23Market Cap: $1.2 BilSector: Health CareIndustry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About iRadimed (IRMD)

Key Risks to the Business:

MRI Compatible IV Infusion Pump Systems

MRI Compatible Patient Vital Signs Monitoring Systems

Share Repurchases

Share Issuance

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets vs. iRadimed (IRMD)

INDUSTRY: Life Sciences Tools & Services

Higher Rev Chg 3Y Avg | Lower P/S (Values for IRMD: 16.4% | 14.2x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for IRMD: 16.4% | 45.5x)

Higher Rev Chg LTM (Value for IRMD: 14.4%)

Higher Rev Chg 3Y Avg (Value for IRMD: 16.4%)

Higher CFO/Rev LTM (Value for IRMD: 29.8%)

Higher FCF/Rev LTM (Value for IRMD: 19.7%)

Higher Total Yield (Value for IRMD: 2.3%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for IRMD: 16.4% | 14.2x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for IRMD: 16.4% | 45.5x)

Higher Rev Chg LTM (Value for IRMD: 14.4%)

Higher Rev Chg 3Y Avg (Value for IRMD: 16.4%)

Higher Op Mgn LTM (Value for IRMD: 31.2%)

Higher CFO/Rev LTM (Value for IRMD: 29.8%)

Higher FCF/Rev LTM (Value for IRMD: 19.7%)

Higher Total Yield (Value for IRMD: 2.3%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for IRMD: 16.4% | 14.2x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for IRMD: 16.4% | 45.5x)

Higher Rev Chg LTM (Value for IRMD: 14.4%)

Higher Rev Chg 3Y Avg (Value for IRMD: 16.4%)

Higher Op Mgn LTM (Value for IRMD: 31.2%)

Higher CFO/Rev LTM (Value for IRMD: 29.8%)

Higher FCF/Rev LTM (Value for IRMD: 19.7%)

Higher Total Yield (Value for IRMD: 2.3%)

Best Bets in Health Care

P/EBIT (Value for IRMD: 45.5x)

P/E (Value for IRMD: 52.9x)

Rev Chg 3Y Avg (Value for IRMD: 16.4%)

Rev Chg LTM (Value for IRMD: 14.4%)

Rev Chg Q (Value for IRMD: 17.0%)

FCF/Rev 3Y Avg (Value for IRMD: 17.0%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Market Price (4/11/2026): $93.23 | Market Cap: $1.2 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (4/11/2026): $93.23
Market Cap: $1.2 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services